Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Bright Minds Biosciences prices $175 million stock offering at $90 per share
-
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
-
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock
-
Lilly moves beyond blockbuster obesity drugs with $1.2 billion Ventyx buy
-
Form 8-K Cantor Fitzgerald Income For: Jan 01
-
Phathom Pharmaceuticals announces public stock offering
-
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Varonis Systems (VRNS) PT Lowered to $50 at Cantor Fitzgerald
-
Cantor Fitzgerald Downgrades BigBear.ai Holdings (BBAI) to Neutral
-
Cantor Fitzgerald Downgrades SoundThinking (SSTI) to Neutral
-
Cantor Fitzgerald Downgrades GitLab Inc (GTLB) to Neutral
-
JFrog (FROG) PT Raised to $80 at Cantor Fitzgerald
-
Arrowhead Pharma (ARWR) Reiterated at Overweight by Cantor Fitzgerald
-
SharkNinja appoints Jason Wortendyke to board of directors
-
SharkNinja Appoints Jason Wortendyke to Its Board of Directors
-
Cantor: 'Large Cap Top Pick: CrowdStrike'
-
EnviroGold Delivers Strong 2025 Execution and Establishes a Clear Path to Commercial Growth in 2026
-
Alumis plans $175 million public stock offering
-
Alumis Announces Proposed Public Offering of Common Stock
-
Bright Minds Biosciences launches $100 million public offering
-
Bright Minds Biosciences Announces Launch of US$100 Million Public Offering
-
Celldex Therapeutics (CLDX) Reiterated at Overweight by Cantor Fitzgerald
-
Structure Therapeutics (GPCR) Reiterated at Overweight by Cantor Fitzgerald
-
Xenon Pharmaceuticals (XENE) PT Raised to $55 at Cantor Fitzgerald
-
CoreWeave (CRWV) Well-Positioned to Benefit From AI Hyperscale Demand: Analyst
-
Hyperion DeFi appoints Hyunsu Jung as chief executive officer
-
Cantor Fitzgerald Reiterates Overweight Rating on ServiceNow (NOW) as TAM Expands Through M&A
-
Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer
-
Cantor Fitzgerald Highlights Okta, Inc (OKTA) Stock as a Contrarian Play
-
Cantor Fitzgerald Reiterates Overweight Rating on Stoke Therapeutics (STOK)
-
Cantor Fitzgerald: We expect Semiconductors to Outperform in 2026.
-
Cantor Fitzgerald on Intuitive Machines Inc. (LUNR): 'We Remain Very Bullish...Ahead of Near-Term Catalysts'
-
Cantor Fitzgerald Reiterates Overweight Rating on Rocket Lab USA (RKLB)
-
Lucid Group Inc. (LCID): Launch of Midsize the Most Material Catalyst, Says Cantor Analyst
-
Cantor Fitzgerald Reiterates Neutral Rating on Rivian Automotive Inc (RIVN)
-
Cantor Fitzgerald Reiterates Overweight Rating on Tesla (TSLA)
-
Cantor Fitzgerald Announces Successful First Close of O’Connor Transaction
-
Riot Platforms establishes $500 million at-the-market stock offering program
-
CYBIN launches $100 million at-the-market equity program
-
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
-
Soulpower files confidential S-4 draft for business combination
-
Soulpower Acquisition Corporation (NYSE:SOUL) and SWB Holdings Announce Confidential Filing of Draft Registration Statement on Form S-4 with the SEC
-
SAB Biotherapeutics establishes $75 million at-the-market offering program
-
Form DEFA14A CANTOR FITZGERALD INFRAS
-
Top Fintech Stocks to Watch in 2026 as Tokenization and AI Transform Finance
-
FDA;s messaging is positive for Travere Therapeutics (TVTX) - Cantor Fitzgerald
-
Form 3 CANTOR FITZGERALD INFRAS For: Jun 30 Filed by: Ferri William J
-
Cantor Fitzgerald Starts Vizsla Silver Corp (VZLA:CN) (VZLA) at Buy
-
Cantor Fitzgerald Starts ArriVent BioPharma (AVBP) at Overweight
-
Form DEFA14A CANTOR FITZGERALD INFRAS

